[-] Show simple item record

dc.contributor.authorMangematin, V.eng
dc.contributor.authorLemarié, Stéphaneeng
dc.contributor.authorCatherine, Davideng
dc.coverage.spatialFranceeng
dc.date.issued2001eng
dc.descriptionIncludes bibliographical references.eng
dc.description.abstractEuropean policy to promote small- and medium-sized enterprise (SMEs) creation seems to be successful in France, judging by the high rate of new business formation. Yet French firms remain very small compared to United States (US) firms, employing less than 40 employees on average, as opposed to 140 in the US. This prompts the question of their future. Are all biotechnology SMEs destined to expand, disappear or be bought out? Or is there a place for small businesses that cater to a particular market niche? This paper argues that agbiotech SMEs do have a specific trajectory that will allow them to continue to exist, at least in the medium term. However, they will continue to have a low potential for growth because (1)they are older and more mature than other biotech SMEs and yet remain small; and (2) they currently face a difficult venture capital market because of the uncertainty surrounding investment in agbiotech within Europe.eng
dc.identifier.citationAgBioForum, 4(2) 2001: 98-104.eng
dc.identifier.issn1522-936Xeng
dc.identifier.urihttp://hdl.handle.net/10355/336eng
dc.languageEnglisheng
dc.publisherAgBioForumeng
dc.relation.ispartofcollectionAgBioForum, vol. 4, no. 2 (2001)eng
dc.source.urihttp://www.agbioforum.missouri.edu/v4n2/v4n2a04-mangematin.htmeng
dc.subjectsmall and medium sized enterprise (SME) ; growtheng
dc.subject.lcshBiotechnology industrieseng
dc.subject.lcshSmall businesseng
dc.titleFrench Ag-Biotech SMEs: Development Prospectseng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record